Group 1 - The stock of Aojing Medical (688613) closed at 22.56 yuan on January 8, 2026, with an increase of 4.44% and a turnover rate of 5.78% [1] - The total trading volume was 79,200 hands, with a transaction amount of 176 million yuan [1] - On January 8, the net inflow of main funds was 26.66 million yuan, accounting for 15.13% of the total transaction amount, while retail investors had a net outflow of 20.43 million yuan, accounting for 11.6% [1] Group 2 - In the financing and securities lending data, the financing buy amounted to 30.56 million yuan, with a net financing increase of 11.78 million yuan [2] - The total financing and securities lending balance was 198 million yuan [2] - Aojing Medical's main business includes the research, production, and sales of high-end biomedical materials and related medical devices [3] Group 3 - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 56.02 million yuan, a year-on-year increase of 16.54%, and a net profit of 5.97 million yuan, up 237.64% [3] - The company's debt ratio was 6.22%, with a gross profit margin of 68.9% [3]

（文章来源：证券日报） 证券日报网讯 1月7日，奥精医疗发布公告称，公司2025年度财务审计机构立信会计师事务所内部调 整，签字注册会计师由常明、周末变更为田伟、周末，继续完成本年度审计工作。 ...

二、变更人员信息 2 项目签字注册会计师田伟先生，2009年成为中国注册会计师，2009年开始从事 上市公司审计业务，2018年开始在立信会计师事务所执业，2025年开始为奥精医疗 科技股份有限公司提供审计服务。 证券代码： 688613 证券简称： 奥精医疗 公告编号： 2026-002 奥精医疗科技股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2025年4月25日召开第二 届董事会第十三次会议，于2025年5月16日召开2024年年度股东大会，审议通过《 关于公司续聘立信会计师事务所（特殊普通合伙）为公司2025年度财务审计机构的 议案》，同意聘任立信会计师事务所（特殊普通合伙）（以下简称"立信会计师事 务所"）为公司2025年度财务审计机构和内部控制审计机构。具体内容详见公司于 2025年4月26日在上海证券交易所网站（www.sse.com.cn）披露的《奥精医疗科技 股份有限公司关于续聘会计师事务所的公告》（公告编号：20 ...

Core Viewpoint - The Beijing Aojing Medical Equipment Co., Ltd., a wholly-owned subsidiary of Aojing Medical, has successfully been selected for the "3+N" alliance volume-based procurement project for hemostatic materials, with its product "Aoyuying®" absorbable collagen hemostatic sponge included in the procurement catalog [1][4]. Group 1: Procurement Results - The "3+N" alliance is the first cross-provincial volume-based procurement regional alliance in China, consisting of Beijing, Tianjin, and Hebei, along with other participating provinces [3]. - The alliance aims to reduce patient burdens by guiding the rational clinical use of high-quality medical consumables through regional linkage and volume-based pricing [3]. Group 2: Product Details - The Aoyuying® absorbable collagen hemostatic sponge is a Class III medical device made from high-purity collagen, designed for rapid hemostasis and tissue repair support [4]. - The product works by physically adsorbing blood and activating endogenous coagulation mechanisms, establishing a stable hemostatic environment in surgical areas [4]. - Aoyuying® is widely used in various surgical fields, including general surgery, orthopedics, obstetrics and gynecology, and dentistry, and is available in multiple specifications to meet different surgical needs [4]. Group 3: Market Potential - According to DIResearch, the global collagen sponge market is projected to reach approximately $296 million by 2025 and $456 million by 2032, with a compound annual growth rate (CAGR) of 6.36% [4]. - The ongoing promotion of volume-based procurement mechanisms is expected to provide broader application opportunities for products with stable quality and reliable supply [5].

证券代码：688613 证券简称：奥精医疗 公告编号：2026-001 奥精医疗科技股份有限公司 董事及高级管理人员提前终止减持计划 2025 年 12 月 15 日至 2025 年 12 月 31 日，公司分别收到仇志烨先生、 田国峰先生、宋天喜先生、王玲女士出具的《关于减持股份计划结果的告知函》。 截至 2025 年 12 月 31 日，仇志烨先生通过集中竞价交易方式减持公司股份 95000 股，占公司总股本的 0.07%；王玲女士通过集中竞价交易方式减持公司股份 70312 股，占公司总股本的 0.05%，宋天喜先生通过集中竞价交易方式减持公司股份 50000 股，占公司总股本的 0.04%；田国峰先生通过集中竞价交易方式减持公司 股份 37500 股，占公司总股本的 0.03%，截至本公告披露日，本次减持股份计划 已实施完毕。 | 股东名称 | 仇志烨 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | □否 | | | 直接持股 5%以上股东 | □是 | □否 | | | 董事、监事和高级管理人员 | √是 | □否 | | ...

Group 1 - The core viewpoint of the news is that Aojing Medical has seen a stock price increase of 5.02%, reaching 21.33 yuan per share, with a total market capitalization of 2.922 billion yuan as of the report date [1] - Aojing Medical specializes in high-end biomedical materials and related medical device products, with its main business revenue composition being: 骼金 74.91%, 颅瑞 16.35%, 齿贝 4.15%, 口腔种植体 2.70%, and others 1.87% [1] - The company is located in Beijing and was established on December 22, 2004, with its listing date on May 21, 2021 [1] Group 2 - Among the top ten circulating shareholders of Aojing Medical, a fund under Rongtong Fund has entered the list, holding 2.4 million shares, which accounts for 1.75% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 1.816 billion yuan and has achieved a return of 8.57% this year, ranking 6064 out of 8155 in its category [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 135 days, with the fund's total asset scale at 5.957 billion yuan [3]

Core Viewpoint - The recent shareholding changes of senior management at Aojing Medical (688613) indicate a minor reduction in ownership, coinciding with a slight decline in the company's stock price [1] Group 1: Shareholding Changes - On December 29, 2025, senior management member Wang Ling reduced her holdings by 2,500 shares, representing 0.0018% of the company's total share capital [1] - The company's stock price decreased by 0.91% on the same day, closing at 20.6 yuan [1] Group 2: Financing and Margin Data - Over the past five days, the stock experienced a net outflow of 4.2848 million yuan in financing, indicating a decrease in financing balance [1] - There was no net inflow in margin trading, with the margin balance increasing [1] Group 3: Analyst Ratings - There have been no institutional ratings for the stock in the last 90 days [1]

Group 1 - The core point of the article is that Aojing Medical (688613) experienced a stock price decline of 2.58% to 20.79 yuan as of December 26, 2025, with a trading volume of 36,100 shares and a turnover of 75.52 million yuan [1] - On December 26, the net outflow of main funds was 10.76 million yuan, while speculative funds saw a net inflow of 10.94 million yuan, and retail investors had a net outflow of 183,300 yuan [1][3] - Aojing Medical announced that shareholder Beijing Qilun Tianyou Venture Capital Co., Ltd. reduced its holdings by 300,000 shares from December 22 to December 25, representing 0.22% of the total share capital, decreasing its holding from 6.18% to 5.96% [2][3] Group 2 - The reduction in holdings by Beijing Qilun Tianyou was part of a previously disclosed reduction plan and did not trigger a mandatory bid, nor did it affect the company's governance structure or ongoing operations [2][3] - The stock price increased by 5.75% during the period of the share reduction, closing at 21.34 yuan on December 25 [1]

截至2025年12月26日收盘，奥精医疗（688613）报收于20.79元，较上周的20.18元上涨3.02%。本周， 奥精医疗12月22日盘中最高价报22.29元。12月22日盘中最低价报20.19元。奥精医疗当前最新总市值 28.48亿元，在医疗器械板块市值排名112/127，在两市A股市值排名4636/5178。 高管增减持 2025年12月24日，公司高级管理人员王玲减持312股，占总股本0.0002%。期间股价上涨0.76%，当日收 盘报21.25元。 2025年12月22日，董事仇志烨与董事宋天喜合计减持6.5万股，占总股本0.0474%。期间股价上涨 9.22%，当日收盘报22.04元。 公司公告汇总 奥精医疗于2025年12月24日公告称，因立信会计师事务所内部调整，公司2025年度审计项目质量控制复 核人由单大信变更为王芳。王芳为中国注册会计师，自2012年起在立信执业，2025年开始为公司提供审 计服务，近三年未受过处罚，符合独立性要求。本次变更不影响审计工作安排，不会对公司年度审计产 生不利影响。 本周关注点 奥精医疗发布关于持股5%以上股东权益变动触及1%刻度的提示性公告，北京奇伦天佑 ...

关于持股 5%以上股东权益变动触及 1%刻度的提示性公告 股东北京奇伦天佑创业投资有限公司（以下简称"奇伦天佑"）保证向奥精医疗科 技股份有限公司（以下简称"公司"）提供的信息真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：688613 证券简称：奥精医疗 公告编号：2025-067 奥精医疗科技股份有限公司 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 6.18% | | | | 权益变动后合计比例 | 5.96% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、信息披露义务人及其一致行动人的基本信息 1、身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | ☑其他5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适 ...